• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    COO Devall Christopher Franklin was granted 10,000 shares, increasing direct ownership by 7% to 155,702 units (SEC Form 4)

    12/12/25 9:48:09 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DOMH alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Devall Christopher Franklin

    (Last) (First) (Middle)
    725 5TH AVENUE
    22ND FLOOR

    (Street)
    NEW YORK NY 10022

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Dominari Holdings Inc. [ DOMH ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    COO
    3. Date of Earliest Transaction (Month/Day/Year)
    12/11/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 12/11/2025 A 10,000(1) A (1) 155,702 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. On December 11, 2025, the Reporting Person was granted 10,000 shares of restricted stock pursuant to the 2022 Equity Incentive Plan, by and between the Reporting Person and the Issuer. The granted shares will vest on 12/11/2026.
    /s/ Christopher Franklin Devall 12/12/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $DOMH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DOMH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $DOMH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Ledwick Tim S

    4 - Dominari Holdings Inc. (0000012239) (Issuer)

    3/25/26 8:10:56 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Hayes Anthony

    4 - Dominari Holdings Inc. (0000012239) (Issuer)

    3/24/26 9:23:32 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Haug Kyle

    4 - Dominari Holdings Inc. (0000012239) (Issuer)

    3/24/26 9:23:14 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DOMH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: CEO Hayes Anthony bought $89,054 worth of shares (23,000 units at $3.87), increasing direct ownership by 1% to 1,750,873 units (SEC Form 4)

    4/A - Dominari Holdings Inc. (0000012239) (Issuer)

    12/10/25 9:22:01 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: President Wool Kyle Michael bought $96,798 worth of shares (25,000 units at $3.87), increasing direct ownership by 2% to 1,211,828 units (SEC Form 4)

    4/A - Dominari Holdings Inc. (0000012239) (Issuer)

    12/10/25 9:20:35 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President Wool Kyle Michael decreased direct ownership by 1% to 2,453,817 units (SEC Form 4)

    4 - Dominari Holdings Inc. (0000012239) (Issuer)

    12/10/25 7:54:17 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DOMH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    The Rise of the American Drone Industry

    NEW YORK, June 2, 2026 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) today issued the following letter to shareholders: Dear Shareholder,The rise of drones in our society has become ubiquitous. Whether it's the discussion of their use to make deliveries, their use to cover sporting events, or their constant presence when discussing conflicts in the middle east, drones are everywhere. And at Dominari, we are proud to play our part in building and supporting this growing American industry.Since our inception, Dominari has been involved in supporting this important new facet

    6/2/26 8:00:00 AM ET
    $DOMH
    $JFB
    $UMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    General Bldg Contractors - Nonresidential Bldgs
    Consumer Discretionary

    Dominari Holdings Congratulates Cerebras Systems on "Blockbuster" Initial Public Offering

    Shares Skyrocket in Debut as AI Mania Grips Wall Street According to ReutersNEW YORK, May 15, 2026 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) ("Dominari" or the "Company") congratulates Cerebras Systems (NASDAQ:CBRS), on its Initital Public Offering, which has been called a "Blockbuster Debut" as the next hot AI stock, by Investor's Business Daily. On May 14, 2026, Cerebras stock opened at $185.00 and closed $126 higher at $311.07 per share, an approximate 68% increase on its first day of trading. Dominari Securities' SPV 1 & 2 invested early in Cerebras, at $39.00 per

    5/15/26 8:00:00 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dominari Holdings Issues Shareholder Letter

    Company Reports Revenue of $35.8 million up 395% from prior yearTotal Capital invested across all SPV Series: approximately $292 millionRecord Date of May 15th for $9 Million Dividend PaymentNEW YORK, May 13, 2026 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) ("Dominari" or the "Company") today issued the following letter to shareholders: Dear Shareholder,As we approach mid-year, I want to take this opportunity to thank you for being a Dominari shareholder and provide you with some updates.10Q SummaryThe year is off to a strong start. As noted in our 10Q just filed with t

    5/13/26 8:00:00 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DOMH
    SEC Filings

    View All

    Dominari Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Dominari Holdings Inc. (0000012239) (Filer)

    5/27/26 5:00:42 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Dominari Holdings Inc.

    10-Q - Dominari Holdings Inc. (0000012239) (Filer)

    5/12/26 9:42:51 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dominari Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Dominari Holdings Inc. (0000012239) (Filer)

    3/31/26 9:20:25 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DOMH
    Leadership Updates

    Live Leadership Updates

    View All

    Dominari Expands Strategic Leadership with Appointment of Ambassador Jamie McCourt to Advisory Board

    Dominari Withdraws $2 Billion Shelf Registration NEW YORK, Dec. 8, 2025 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) today announced a major enhancement to its strategic leadership with the appointment of Ambassador Jamie McCourt to the Advisory Board of Dominari Securities. Separately, the company has formally withdrawn its previously filed $2 billion shelf registration statement, reflecting confidence in its financial position and growth outlook. Globally recognized diplomat, executive and entrepreneur Ambassador Jamie McCourt Joins Advisory Board Ambassador McCourt

    12/8/25 8:30:00 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dominari Securities Receives Approval as a Limited Underwriting Member of the New York Stock Exchange

    Enables direct participation in underwriting activities conducted through NYSE and NYSEAmerican platforms NEW YORK, Oct. 9, 2025 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) ("Dominari" or the "Company") today announced that its wholly owned subsidiary, Dominari Securities LLC, has been approved as a Limited Underwriting member of the New York Stock Exchange and NYSE American Equities (the "Exchanges") effective October 8, 2025. This approval marks an important regulatory milestone for Dominari Securities as it continues to expand its capabilities within U.S. capital m

    10/9/25 8:00:00 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dominari Securities Appoints Communications and Growth Strategist Brian Parsley to Board

    Accomplished entrepreneur and global speaker to strengthen firm's marketing, investor engagement and strategic communications to help drive growth NEW YORK, Sept. 10, 2025 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH), today announced the appointment of Brian Parsley to its Board of Directors. Parsley, an accomplished entrepreneur, behavioral analyst and internationally recognized speaker, will support the firm's growth by enhancing its marketing, investor outreach and overall communications strategy. Mr. Parsley has more than 30 years of experience in entrepreneurship,

    9/10/25 8:30:00 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DOMH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Dominari Holdings Inc.

    SC 13D/A - Dominari Holdings Inc. (0000012239) (Subject)

    6/13/24 8:56:04 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Dominari Holdings Inc.

    SC 13D/A - Dominari Holdings Inc. (0000012239) (Subject)

    6/13/24 4:32:07 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DOMH
    Financials

    Live finance-specific insights

    View All

    Dominari Holdings Issues Shareholder Letter

    Company Reports Revenue of $35.8 million up 395% from prior yearTotal Capital invested across all SPV Series: approximately $292 millionRecord Date of May 15th for $9 Million Dividend PaymentNEW YORK, May 13, 2026 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) ("Dominari" or the "Company") today issued the following letter to shareholders: Dear Shareholder,As we approach mid-year, I want to take this opportunity to thank you for being a Dominari shareholder and provide you with some updates.10Q SummaryThe year is off to a strong start. As noted in our 10Q just filed with t

    5/13/26 8:00:00 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dominari Q1 Revenue Increases by 395% Over Q1 2025

    Underwriting revenues increased over five-fold NEW YORK, May 13, 2026 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) ("Dominari" or the "Company"), today announced highlights of its financial results for the quarter ended March 31, 2026, which were filed with the Securities and Exchange Commission ("SEC") in the Company's quarterly SEC Form 10Q. The Company stated that:  "In  the first quarter of 2026,  we experienced continued revenue growth mainly from underwriting services, increased our annual recurring revenue from our management fees that we earn on deals that we bri

    5/13/26 7:00:00 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dominari Holdings Announces Record Date for Cash Dividend

    NEW YORK, May 4, 2026 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) is pleased to announce that its board of directors has authorized a special cash dividend of, in the aggregate, approximately $9 million, or approximately $0.31 per share. The dividend is payable on or about May 29, 2026, to DOMH's common stock shareholders and certain DOMH warrant holders (on an as-exercised basis) of record as of the close of business on May 15, 2025. For additional information about Dominari Holdings Inc., please visit: https://www.dominariholdings.com/About Dominari Holdings Inc.The C

    5/4/26 8:00:00 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care